Microscopic evaluation of the effect of hormone replacement therapy on the endometrium in women who bleed

Gynecological Endocrinology

Volumn 11, Issue SUPPL. 2, 1997, Pages 11-16

  Bergeron, C ^a  

^a Laboratory Cerba   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001902738     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.3109/09513599709152590     Document Type: Review

References (16)

1. Grady, D., Gebretsadik, T., Kerlikowske, K., Ernster, V. and Petitti, D. (1995). Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet. Gynecol., 85, 304-13
2. Voigt, L. F., Weiss, N. S., Chu, J., Daling, J. R., McKnight, D. and van Belle, G. (1991). Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet, 338, 274-7
3. Brinton, L. and Hoover, R. (1993). Estrogen replacement therapy and endometrial cancer risk: unresolved issue. Obstet. Gynecol., 81, 265-71
4. Persson, I., Adami, H. O., Bergkvist, L., Lindgren, A., Pettersson, B., Hoover, R. and Schairer, C. (1989). Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. Br. Med. J., 298, 147-51
5. Leather, A. T., Sawas, M. and Studd, J. W. W. (1991). Endometrial histology and bleeding patterns after 8 years of continuous combined estrogen and progestagen therapy in postmenopausal women. Obstet. Gynecol., 78, 1008-10
6. Hoffman, K., Nekhlyudov, L. and Deligdisch, L. (1995). Endometrial carcinoma in elderly women. Gynecol. Oncol, 58, 198-201
7. Tax, L., Goorissen, E. M. and Kicovic, P. M. (1987). Clinical profile of Org OD14. Maturitas, Suppl. 1, 3-13
8. Ginsburg, J., Prelevic, G., Butler, D. and Okolo, S. (1995). Clinical experience with tibolone (Livial®) over 8 years. Maturitas, 21, 71-6
9. Siseles, N. O., Halperin, H., Benencia, H. J., Berg, G., Pilnik, S., Mesch, V., Arrighi, B. and Wikinski, R. W. W. (1995). A comparative study of two hormone replacement therapy regimens on safety and efficacy variables. Maturitas, 21, 201-10
10. Geusens, P., Dequeker, J., Gielen, J. and Schot, L. P. (1991). Non-linear increase in vertebral density induced by a synthetic steroid (Org OD14) in women with established osteoporosis. Maturitas, 23, 155-62
11. Lindsay, R., Hart, D. M. and Kraszewski, A. (1978). Prospective double blind trial of synthetic steroid (Org OD14) for preventing postmenopausal osteoporosis. Br. Med. J., 280, 1207-9
12. Punnonen, R., Luikko, P., Cortes-Prieto, J., Eydam, F., Milojevic, S., Trevoux, R., Chryssikopoulos, E., Franchi, F., Luis, M. and Kicovic, P. M. (1984). Multicentre study of the effects of Org OD14 on endometrium, vaginal cytology and cervical mucus in postmenopausal and oophorectomized women. Maturitas, 5, 281-6
13. Genazzani, A. R., Benedek-Jaszmann, L. J., Hart, D. M., Andolsek, L., Kicovic, P. M. and Tax, L. (1991). Org OD14 and the endometrium. Maturitas, 13, 243-51
14. Markiewicz, L. and Gurpide, E. (1990). In vitro evaluation of estrogenic, estrogen antagonistic and progestogenic effects of a steroidal drug (Org OD14) and its metabolites on human endometrium. J. Steroid Biochem., 35, 535-42
15. Rymer, J., Fogelman, I. and Chapman, M. G. (1994). The incidence of vaginal bleeding with tibolone treatment. Br. J. Obstet. Gynaecol., 101, 53-66
16. Ginsburg, J. and Prelevic, G. M. (1996). Cause of vaginal bleeding in postmenopausal women taking tibolone. Maturitas, 24, 107-10